Study S000243

The Efficacy of a Once Weekly Glucagon-Like Peptide-1 Agonist on Body Weight/Composition and Metabolic Parameters in Persons With SCI

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03292315
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 5
Start: 2018-10-16
Primary completion: 2020-03-01
Lead sponsor: James J. Peters Veterans Affairs Medical Center
Conditions: Spinal Cord Injuries; Insulin Resistance; Pre Diabetes; Obesity
Interventions: DRUG:Semaglutide 1MG Injection [Ozempic]; OTHER:No Intervention
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Body Weight [Baseline, Week 13, Week 26]
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) [Baseline, Week 13, Week 26]
Homeostatic Model Assessment of Beta-Cell Function (HOMA-B) [Baseline, Week 13, Week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008321	Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series. Cirnigliaro CM, The journal of spinal cord medicine	2024	Randomized trial	PMID 37158751 DOI	cites ClinicalTrials.gov:NCT03292315; registry reference DERIVED:37158751